The Olmsted NAFLD Epidemiology Study (TONES)
Public ClinicalTrials.gov record NCT04365855. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of adults with NAFLD and NASH to validate models of NAFLD diagnosis and determine long-term outcomes.
Study identification
- NCT ID
- NCT04365855
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 800 participants
Conditions and interventions
Interventions
- Blood draw Other
- Fibro Scan Procedure
- Liver biopsy Procedure
- Magnetic Resonance Elastography Diagnostic Test
Other · Procedure · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2020
- Primary completion
- May 31, 2028
- Completion
- May 31, 2028
- Last update posted
- Jan 15, 2026
2020 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Non-Alcoholic Fatty Liver Disease trials
Other public records listing Non-Alcoholic Fatty Liver Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT06005012: Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM Active, not recruiting
- NCT07403604: Effect of Insulin Lowering on Lipogenesis Recruiting
- NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH Active, not recruiting
- NCT04951219: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) Active, not recruiting
- NCT03884075: Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) Recruiting
- NCT07221227: A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04365855, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2026 · Synced Jul 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04365855 live on ClinicalTrials.gov.